Targeting BRPF3 moderately reverses olaparib resistance in high grade serous ovarian carcinoma.

导出 OA

翻译打印收藏纠错

第一作者： Benjamin G,Bitler

第一单位： Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado School of Medicine, Aurora, Colorado, USA.

作者： Benjamin G,Bitler ^[1] ; Courtney A,Bailey ^[1] ; Tomomi M,Yamamoto ^[1] ; Alexandra,McMellen ^[2] ; Hyunmin,Kim ^[3] ; Zachary L,Watson ^[1]

作者单位： Department of Obstetrics and Gynecology, Division of Reproductive Sciences, University of Colorado School of Medicine, Aurora, Colorado, USA. ^[1] Department of Pediatrics, Section of Hematology, Oncology, and Bone Marrow Transplantation, University of Colorado School of Medicine, Aurora, Colorado, USA. ^[2] Case Western Reserve University School of Medicine, Cleveland, Ohio, USA. ^[3]

关键词 BRPF3 H3K14ac HGSOC PARP inhibitor ovarian cancer resistance

主题词女(雌)性(Female);人类(Humans);卵巢肿瘤(Ovarian Neoplasms);细胞系, 肿瘤(Cell Line, Tumor);组蛋白类(Histones)

DOI 10.1002/mc.23610

PMID 37493106

发布时间 2024-11-02

翻译满意度评价：

准确一般字义偏差语意偏离译文作用小提交